Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate.
about
Etanercept for the treatment of rheumatoid arthritisCellular targeting in autoimmunityNeutrophils and Granulocytic MDSC: The Janus God of Cancer ImmunotherapyWhy CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritisInternational Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.Targeting chemokines in proteinuria-induced renal disease.Emerging therapies for rheumatoid arthritis.Advances in understanding the pathogenesis of autoimmune disorders: focus on chemokines and lymphocyte trafficking.Emerging immunotherapies for rheumatoid arthritis.Inflammatory Cell Migration in Rheumatoid Arthritis: A Comprehensive Review.Successes and failures of chemokine-pathway targeting in rheumatoid arthritis.Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis.The Multifunctional Role of the Chemokine System in Arthritogenic Processes.The multiple chemokine-binding bovine herpesvirus 1 glycoprotein G (BHV1gG) inhibits polymorphonuclear cell but not monocyte migration into inflammatory sites.What is the future of CCR5 antagonists in rheumatoid arthritis?Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose.Overcoming hurdles in developing successful drugs targeting chemokine receptors.The Role of Macrophages in the Response to TNF Inhibition in Experimental Arthritis.Protective role for CCR5 in murine lupus nephritis.CCR5 deficiency does not reduce hypertensive end-organ damage in mice.Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately respondinA cytokine protein-protein interaction network for identifying key molecules in rheumatoid arthritis.
P2860
Q24202751-A63C5A52-D3C9-4257-9405-05692744CB92Q26824580-A9EF401D-67E5-499F-BAA2-6A085798FD22Q28069360-39FD88FF-9CB3-46B9-A3DB-31542D0F8434Q28742993-1519CEFD-9F06-4858-AD0F-35F244C304FAQ37432097-B44615F3-9D76-46F0-9D25-ADF45AB0271DQ38026076-9273EEAD-C00F-40D8-9C7D-6D2BE4B93967Q38110963-7ED49F5F-5439-4694-837D-17330B91FFC4Q38155907-56C38280-B68B-4A8A-868D-DE1BF9E5DF8FQ38188862-40ED2643-CD28-45C2-96A8-F2F3A0AA5480Q38618883-32F8562E-8EB2-4A13-9FE7-92E5731FACE1Q38647749-D718D372-98FA-496B-912E-6AF6791724CBQ38939820-E7656E0D-38CA-45CB-8A90-A37030CACCDCQ39158831-8F311615-3480-43D3-9659-D31CCF38C413Q41945153-7D809653-66B6-4233-BAE1-FF2FEDF3F8F1Q42326321-0A0BADBE-90EB-4435-A37D-849A92E6C1EBQ45999111-40D1D681-EB0B-4A8D-981B-0867D3E8E442Q46441158-66468635-E12F-4F31-988C-88257E7E57C4Q47390076-D06E0E95-43ED-4A3C-AE60-A0CF781B2AF9Q47989935-0E1963F5-68A7-4DC0-8457-E7B817ABAF94Q53191263-1CE9535B-B378-4FB3-ABBD-691F380224BAQ54967818-1FFB9AD5-0A91-4780-BDBB-BA5BFD5DB6CBQ55496778-DFB7F4B3-A035-4FFD-BD67-501DC33202D0
P2860
Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Preclinical and clinical inves ...... hritis receiving methotrexate.
@en
Preclinical and clinical inves ...... hritis receiving methotrexate.
@nl
type
label
Preclinical and clinical inves ...... hritis receiving methotrexate.
@en
Preclinical and clinical inves ...... hritis receiving methotrexate.
@nl
prefLabel
Preclinical and clinical inves ...... hritis receiving methotrexate.
@en
Preclinical and clinical inves ...... hritis receiving methotrexate.
@nl
P2093
P2860
P356
P1476
Preclinical and clinical inves ...... hritis receiving methotrexate.
@en
P2093
Daniëlle M Gerlag
ESCAPE Study Group
Mark Layton
Martin Braddock
Paul P Tak
Sally Hollis
Zoltán Szekanecz
P2860
P304
P356
10.1002/ART.27652
P577
2010-11-01T00:00:00Z